Last reviewed · How we verify
Bupropion SR
Bupropion SR, marketed by the Medical University of South Carolina, is an established treatment in the pharmaceutical market with a key composition patent expiring in 2028. Its primary strength lies in its well-established market presence and long-term use for its primary indication. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Bupropion SR |
|---|---|
| Also known as | Wellbutrin XL, Zyban, Wellbutrin SR, Zyban SR, Wellbutrin |
| Sponsor | Medical University of South Carolina |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment (PHASE3)
- Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors (PHASE3)
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial (PHASE4)
- Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use (NA)
- Reward-specific Changes of the Chemical Messenger Dopamine in the Brain of Healthy and Depressed People (PHASE4)
- Varenicline and Bupropion for Alcohol Use Disorder (PHASE2)
- Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy (PHASE2, PHASE3)
- Bupropion in the Treatment of Methamphetamine Dependence (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bupropion SR CI brief — competitive landscape report
- Bupropion SR updates RSS · CI watch RSS
- Medical University of South Carolina portfolio CI